Next Article in Journal
Natural Products for Cancer Prevention and Therapy: Progress, Pitfalls and Promise
Previous Article in Journal
The Effects of Wortmannin and EGCG and Combined Treatments on MDA-MB-231 Breast Cancer Cell Lines via Inactivation of PI3K Signaling Pathway
Article Menu

Article Versions

Export Article

Open AccessAbstract
Proceedings 2017, 1(10), 985; doi:10.3390/proceedings1100985

Characterization of Cycloartane-Type Sapogenol Derivatives for Prostate Cancer Chemoprevention

1
Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Ege University, Izmir 35040, Turkey
2
Department of Bioengineering, Faculty of Engineering, Ege University, Izmir 35040, Turkey
3
Cancer Biology Laboratory, Department of Chemistry, Graduate School of Natural and Applied Sciences, Ege University, Izmir 35040, Turkey
4
Department of Bioengineering, Faculty of Engineering, Izmir Institute of Technology, Izmir 35430, Turkey
Presented at the 2nd International Conference on Natural Products for Cancer Prevention and Therapy, Kayseri, Turkey, 8–11 November 2017.
*
Author to whom correspondence should be addressed.
Published: 15 November 2017
Download PDF [349 KB, uploaded 15 November 2017]

Abstract

Inhibition of inflammation-induced carcinogenesis is an efficient therapeutic strategy for cancer chemoprevention as use of anti-inflammatories was reported to decrease the cancer risk. In this study, we aimed to investigate the inhibition potential of semi-synthetic derivations of cycloartane-type sapogenol molecules on inflammation-related tumorigenic mechanisms in LNCaP prostate cancer cells. Inflammatory microenvironment was stimulated by TNFα/inflammatory conditioned media (CM). WST1/Xcelligence (proliferation), luciferase reporter (NFkB activity), immunoblotting, DCFH (ROS) and Griess (NO release) methods were used. It has been found that TNFα-induced NFkB activation was suppressed by both astragenol and cycloastragenol derivatives through inhibition of IkB phosphorylation. Further, the loss of Androgen Receptor, NKX3.1 and p53 due to inflammatory microenvironment was partially restored. In addition, tumorigenic cellular events such as increased NO release and intracellular ROS levels were both suppressed by the molecules. Inhibition of B-catenin pathway at anti-inflammatory concentrations was determined through decreased levels of pAkt(S473), total B-catenin and B-catenin(S552) induced by both lipopolysaccharide and CM treatments in inflammatory microenvironment. Finally, saponin molecules were found to suppress the proliferation and migration of prostate cancer cells at apoptotic concentrations. Therefore, it is suggested that anti-inflammatory activity of these sapogenol derivatives through NFkB inhibition make them promising agents for chemoprevention of inflammation-related prostate carcinogenesis.
Keywords: saponin; cancer chemoprevention; androgen receptor; NKX3.1; astragenol; cycloastragenol saponin; cancer chemoprevention; androgen receptor; NKX3.1; astragenol; cycloastragenol
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Debelec-Butuner, B.; Ozturk, M.B.; Tag, O.; Akgun, I.H.; Bedir, E.; Korkmaz, K.S. Characterization of Cycloartane-Type Sapogenol Derivatives for Prostate Cancer Chemoprevention. Proceedings 2017, 1, 985.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Proceedings EISSN 2504-3900 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top